Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
To own Veeva Systems, you have to believe life sciences customers will keep deepening their use of Veeva’s cloud and AI agents across critical workflows, not just CRM. The latest quarter’s higher guidance and large Vault CRM wins appear to reinforce AI as the key near term catalyst, while also heightening the importance of maintaining differentiation against larger platform competitors, which remains one of the biggest risks to the story today.
Among the recent announcements, Biogen and Regeneron’s global commitments to Vault CRM stand out as most relevant to this earnings beat. These deals support the idea that Veeva’s AI infused CRM and Commercial Evidence tools are gaining traction with top tier customers, which ties directly into the catalyst around expanding multi product suites and embedding agentic capabilities more deeply across commercial workflows.
Yet, even with these AI wins, investors should be aware of how customer concentration and competitive pressure could still...
Read the full narrative on Veeva Systems (it's free!)
Veeva Systems' narrative projects $4.7 billion revenue and $1.4 billion earnings by 2029.
Uncover how Veeva Systems' forecasts yield a $251.43 fair value, a 9% downside to its current price.
Some of the lowest tier analysts were assuming around US$4.5 billion of revenue and US$1.3 billion of earnings by 2029, which paints a more cautious picture than the upbeat AI driven catalyst narrative, and highlights how your view on whether AI agents truly embed Veeva more deeply into customer workflows can lead to very different conclusions that may need updating after this latest report.
Explore 12 other fair value estimates on Veeva Systems - why the stock might be worth as much as 38% more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Our top stock finds are flying under the radar-for now. Get in early:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com